Innovotech Inc.
TSX VENTURE : IOT

Innovotech Inc.

February 19, 2009 08:00 ET

Innovotech Signs TREK to Manufacture Key Components of bioFILM PA™ Antimicrobial Susceptibility Test

Novel kit designed to help clinicians make better antibiotic treatment decisions to fight difficult biofilm infections

EDMONTON, ALBERTA AND CLEVELAND, OHIO--(Marketwire - Feb. 19, 2009) - Innovotech Inc. (TSX VENTURE:IOT), a leader in biofilm products, and TREK Diagnostic Systems, a preeminent provider of diagnostic systems and susceptibility products for microbiology labs, announced that TREK will manufacture key components of Innovotech's novel biofilm susceptibility test at TREK's Cleveland facility. Innovotech is targeting its initial product launch of the bioFILM PA kit to the Canadian infectious-disease market.

Biofilms are estimated to cause more than 80 percent of all human infections and are inherently resistant to antibiotics. Studies show that bacteria in a biofilm may have a greater than 100-fold increase in resistance to antibiotics when compared to the same bacteria in a planktonic (free-floating) state. Biofilms are particularly dangerous for patients with chronic lung infections, such as cystic fibrosis lung disease, and put patients with catheters, stents, and other medical devices at risk of serious infection. They are also implicated in most chronic hospital-borne infections.

Selecting the right drug at a dosage sufficient enough to completely kill the bacteria is key to preventing resistance. Often doctors must prescribe a cocktail of antibiotics to fight biofilm infections effectively, but there are currently no dependable susceptibility tests to assist doctors in selecting appropriate treatments. Innovotech's manual kit bioFILM PA will enable clinicians to test biofilm samples against a combination of existing antibiotics. Early results indicate that bioFILM PA will provide better treatment outcomes for patients, improved infection-control for hospitals, and substantial cost saving to health systems.

"The agreement will support initial production of bioFILM PA™ for the Canadian market" says Dr. Bhavin Rawal, Product Manager, Innovotech. "TREK's expertise in diagnostic in vitro susceptibility testing, its successful track record with regulatory agencies, and its commitment to quality manufacturing at its facilities in the US and UK are well known. In the future, we may also draw on TREK's knowledge of the susceptibility market as we explore sales growth outside of Canada and line expansion into other products."

According to TREK's Director of Laboratory Services, Cindy Knapp, this agreement expands TREK's service offerings beyond custom susceptibility plates to large-volume contract manufacturing. She commented, "At TREK, we are well-known for our frozen and dried custom panels for clinical and pharmaceutical customers. Now, we are proud to contribute our expertise in susceptibility-products manufacturing to Innovotech's new bioFILM PA kit. Truly an innovative design, the kit targets an important unmet need in the susceptibility marketplace."

About Innovotech Inc: www.innovotech.ca

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry.

About TREK Diagnostic Systems: www.trekds.com

A Magellan Biosciences diagnostics company, TREK is a global manufacturer and distributor of automated systems and consumable products for microbiology-based diagnostic testing designed to improve patient outcomes. Signature product lines include VersaTREK®, Sensititre®, Vizion®, alamarBlue®, para-JEM®, YeastOne®, onSite® and TREK Lab Services. TREK is committed to delivering the highest quality products and services to clinical, pharmaceutical, and veterinary diagnostic laboratories worldwide.

This document contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information